Indications : התוויות

4.1   Therapeutic indications

Rheumatology
- Active phases of systemic vasculitis:
Polyarteritis nodosa (in patients with concomitant positive hepatitis B serology, the duration of treatment should be restricted to two weeks), polymyalgia rheumatica (PMR), PMR with giant cell arteritis, temporal arteritis with acute vision loss; - Active phases of systemic rheumatic disease: systemic lupus erythematosus, mixed connective tissue disease;
- Severe progressive forms of active rheumatoid arthritis, e.g. rapidly destructive forms and/or with extra-articular manifestations;
- Other forms of inflammatory rheumatic arthritis, provided that the severity of symptoms requires it and non-steroidal anti-inflammatory drugs (NSAIDs) cannot be used: Spondylarthritis (ankylosing spondylitis with involvement of peripheral joints, psoriatic arthritis, enteropathic arthropathy with high inflammatory activity); - Reactive forms of arthritis;
- Arthritis in sarcoidosis;
- Severe systemic form of juvenile idiopathic arthritis (Still’s disease) or with iridocyclitis refractory to topical treatment.

Pulmonary and respiratory tract disorders
- Bronchial asthma:
For the long-term treatment of severe chronic asthma (category 4) and for treatment of exacerbations in adults and children.
- Chronic obstructive pulmonary disease (COPD):
For short-term treatment (max. 14 days) of exacerbations;
- Upper respiratory tract disorders:


For short-term treatment of severe forms of allergic rhinitis in adults after failure of all other treatment alternatives, including topical glucocorticoids.

Dermatology
- Oral initial treatment of extensive, severe, acute skin conditions responsive to glucocorticoids, such as:
Allergic skin disease (e.g. acute urticaria, contact dermatitis, drug eruption), atopic eczema (acute exacerbations or extensive weeping eczema), pemphigus vulgaris.

Nephrology
- Minimal change glomerulonephritis;
- Extracapillary proliferative glomerulonephritis (rapidly progressive glomerulonephritis), generally in combination with cytostatics, tapering and ending treatment in Goodpasture’s syndrome; for all other forms, long-term continuation of treatment;
- Idiopathic retroperitoneal fibrosis.